CTSW

Across TCGA pan-cancer cohorts, CTSW mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CTSW data layer compared with 27 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CTSW mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CTSW expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where CTSW mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.705	0.178	<.001	35	view →
HNSC	DFS	Median	All	0.858	0.306	.026	8	view →
LUAD	DFS	Median	III,IV	0.426	0.995	.005	8	view →
LSCC	DFS	Quartile	II,III,IV	0.550	0.929	.017	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CTSW–PDAC (DFS)

Open the PDAC breakdown →